The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 0.5 - 1.5 µg/ml. Predicted molecular weight: 105 kDa.
Use a concentration of 10 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides cAMP and cGMP. Catalyzes the hydrolysis of both cAMP and cGMP to 5'-AMP and 5'-GMP, respectively.
Isoform 1 is present in prostate, pituitary, heart and liver. It is however not present in testis nor in penis, suggesting that weak inhibition by Tadalafil (Cialis) is not relevant (at protein level). Isoform 2 may be expressed in testis. Isoform 4 is expressed in adrenal cortex.
Defects in PDE11A are the cause of primary pigmented nodular adrenocortical disease type 2 (PPNAD2) [MIM:610475]. Primary pigmented nodular adrenocortical disease is a rare bilateral adrenal defect causing ACTH-independent Cushing syndrome. PPNAD2 is characterized by adrenal glands with overall normal size and weight, and multiple small yellow-to-dark brown nodules surrounded by a cortex with a uniform appearance. Microscopically, there are moderate diffuse cortical hyperplasia with mostly nonpigmented nodules, multiple capsular deficits and massive circumscribed and infiltrating extra-adrenal cortical excrescences with micronodules. PPNAD2 leads to Cushing syndrome.
Belongs to the cyclic nucleotide phosphodiesterase family. Contains 2 GAF domains.
The tandem GAF domains bind cGMP, and regulate enzyme activity. The binding of cGMP leading to stimulate the enzyme activity.
ab115624, at 10 µg/ml, staining PDE11A in formalin fixed, paraffin embedded Human prostate tissue by Immunohistochemistry. Following primary incubation slides were incubated with biotinylated anti-goat IgG secondary antibody, alkaline phosphatase-streptavidin and chromogen.
Western blot - Anti-PDE11A antibody (ab115624)
Anti-PDE11A antibody (ab115624) at 1 µg/ml + Human prostate lysate (in RIPA buffer) at 35 µg Developed using the ECL technique